Mexico In-Vitro Diagnostics Market Size
| Study Period | 2019 - 2029 |
| Market Size (2024) | USD 2.07 Billion |
| Market Size (2029) | USD 2.93 Billion |
| CAGR (2024 - 2029) | 7.18 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Mexico In-Vitro Diagnostics Market Analysis
The Mexico In-Vitro Diagnostics Market size is estimated at USD 2.07 billion in 2024, and is expected to reach USD 2.93 billion by 2029, at a CAGR of 7.18% during the forecast period (2024-2029).
The Mexico In-Vitro Diagnostics (IVD) market is undergoing substantial growth, driven by key megatrends and macroeconomic factors reshaping the healthcare environment. The rising burden of both chronic and infectious diseases, along with a heightened focus on early and accurate diagnosis, is fueling demand for sophisticated diagnostic solutions. Additionally, the expanding adoption of point-of-care (POC) diagnostics and government initiatives aimed at enhancing healthcare infrastructure are contributing to the market's acceleration.
High Prevalence of Chronic Diseases: Chronic diseases in Mexico, such as diabetes, cardiovascular conditions, and cancer, are major drivers of the IVD market. Mexico faces a significant rise in diabetes cases, with about 14 million people affected, a number expected to reach 21.2 million by 2045, according to the International Diabetes Federation. This surge necessitates increased use of blood tests, glucose monitors, and self-monitoring devices. Cardiovascular diseases are similarly prevalent, with a growing number of coronary heart disease, stroke, and myocardial infarction cases. The high incidence of these conditions drives demand for diagnostic tools like cholesterol and triglyceride tests, essential for early detection and continuous monitoring.
Growing Usage of Point-of-Care Diagnostics: The rise of POC diagnostics is transforming the IVD landscape in Mexico. POC testing enables immediate results, improving clinical decision-making and patient outcomes, especially in managing chronic diseases and infectious outbreaks. The COVID-19 pandemic has significantly accelerated this trend, with companies introducing advanced IVD tests tailored for both laboratory use and decentralized environments. Co-Diagnostics, for instance, received approval to sell its Logix Smart Influenza A/Influenza B/COVID-19 ""ABC"" Test in Mexico, exemplifying the nation's embrace of innovative diagnostic solutions. The increasing efficiency and convenience of POC diagnostics are expanding their use in diverse settings, from urban hospitals to rural clinics and home care.
The convergence of these market drivers has created a dynamic ecosystem in the Mexico in-vitro diagnostics market. As healthcare evolves with a stronger emphasis on preventive care, the role of IVD in clinical decision-making is becoming pivotal. Both domestic and international firms are heavily investing in research and development, creating new diagnostic solutions tailored to Mexico’s healthcare demands. These innovations are enhancing patient care quality while improving overall healthcare efficiency.
Mexico In-Vitro Diagnostics Market Trends
Molecular Diagnostics: Driving Precision in Mexican Healthcare
Segment Overview: Molecular diagnostics is a cornerstone of Mexico's IVD market, leveraging advanced technology to analyze biological markers for precision in disease detection and treatment. This segment dominates the market, accounting for approximately 39% of the IVD industry in Mexico.
Growth Drivers: Several factors drive molecular diagnostics’ growth, including the rise of infectious diseases, the demand for personalized medicine, and rapid technological advancements. The COVID-19 pandemic significantly boosted the adoption of PCR-based molecular diagnostics, solidifying its importance in pathogen detection. As this segment continues to evolve, its versatility in diagnosing a wide array of diseases ensures sustained market leadership, especially given its ability to deliver precise results across different healthcare environments.
Competitive Landscape: Key market players in molecular diagnostics are continuously innovating to maintain their competitive edge. New miniaturized diagnostic platforms that integrate sample processing, nucleic acid amplification, and detection are revolutionizing the field. Companies are forming strategic partnerships and expanding their presence in Mexico to leverage these innovations. Staying competitive in this rapidly changing landscape requires vigilance in monitoring regulatory changes and technological disruptions that could reshape the market.
Genetic Diseases: Unlocking Growth Potential in Mexican Diagnostics
Segment Trajectory: The genetic diseases segment is experiencing rapid growth, with a projected CAGR of 8.87% from 2024 to 2029. The increasing awareness of genetic disorders, advancements in genomic technology, and a growing focus on preventive healthcare are fueling this growth.
Driving Forces: Several factors are driving this trend, including Mexico’s diverse genetic makeup, which presents unique opportunities for personalized medicine. Increasing investments in bioinformatics and genomics are fostering innovation in genetic testing. Additionally, rising awareness of hereditary disorders and the demand for prenatal and newborn screening is expected to further accelerate growth in this segment.
Strategic Imperatives: To capitalize on the genetic diseases segment, market participants should focus on developing cost-effective, high-throughput genetic testing tailored to Mexico's population. Collaborations with local universities and research institutions will be critical in advancing genetic diagnostics. As genetic technologies such as gene editing gain prominence, companies will need to adapt to potential regulatory and ethical shifts to maintain a competitive position.
Mexico In-Vitro Diagnostics Industry Overview
Global Giants Dominate a Consolidated Market: The Mexico IVD market is heavily dominated by international companies, with imported products representing 87.3% of the market in 2022. Global players, such as Roche Diagnostics, Siemens Healthineers, Abbott Laboratories, and Beckman Coulter, hold a significant share due to their advanced diagnostic platforms and extensive product portfolios.
Market Leaders Leverage Technological Prowess: These multinational corporations dominate the Mexican IVD market by focusing on innovation and R&D. Roche Diagnostics, for instance, offers the COBAS Analyzer, while Abbott Laboratories provides the ALINITY m SYSTEM, both leading diagnostic platforms. Market leaders continue to introduce new, cutting-edge products, ensuring they remain at the forefront of the IVD landscape.
Strategies for Future Success in the Market: To expand market share, companies must focus on several strategic initiatives. First, R&D investments are essential, particularly in molecular diagnostics, where market share is highest. Second, partnerships with Mexican healthcare institutions and universities will unlock opportunities in personalized medicine by leveraging the country's genetic diversity. Third, expanding POC testing capabilities is critical to meet the growing demand for rapid diagnostics. Finally, companies must adapt to Mexico’s evolving regulatory landscape, particularly in response to government initiatives such as the national cancer prevention and control strategy, which is fueling demand for early diagnostic tools.
Mexico In-Vitro Diagnostics Market Leaders
-
BioMérieux
-
Bio-Rad Laboratories, Inc.
-
Sysmex Corporation
-
Thermo Fisher Scientific Inc.
-
Abbott
*Disclaimer: Major Players sorted in no particular order
Mexico In-Vitro Diagnostics Market News
- June 2024: Abbott, a global leader in healthcare, has unveiled Mexico's first and only HIV self-test. As part of its commitment to enhancing access to vital diagnostic tools and bolstering the battle against HIV in Mexico, Abbott introduced two self-testing solutions: the Panbio HIV Self-Test, set to be available to the public at major pharmacies nationwide, and Check Now, a variant exclusively distributed to health organizations and public institutions.
- April 2023: National Institute of Respiratory Diseases, Mexico initiated a clinical trial to evaluate the Point-of-Care Tests for Detecting Opportunistic Infections in Advanced HIV Patients in Mexico City (PREVALIOCDMX)
Mexico In-Vitro Diagnostics Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 High Prevalence of Chronic Diseases
- 4.2.2 Growing Usage of Point-of-Care Diagnostics
-
4.3 Market Restraints
- 4.3.1 Lack of Proper Reimbursement
- 4.3.2 Stringent Regulatory Framework
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD)
-
5.1 By Technique
- 5.1.1 Clinical Chemistry
- 5.1.2 Molecular Diagnostics
- 5.1.3 Immuno Diagnostics
- 5.1.4 Hematology
- 5.1.5 Other Techniques
-
5.2 By Product
- 5.2.1 Instrument
- 5.2.2 Reagent
- 5.2.3 Other Products
-
5.3 By Usability
- 5.3.1 Disposable IVD Devices
- 5.3.2 Reusable IVD Devices
-
5.4 By Application
- 5.4.1 Infectious Disease
- 5.4.2 Cancer/Oncology
- 5.4.3 Cardiology
- 5.4.4 Autoimmune Disease
- 5.4.5 Diabetes
- 5.4.6 Nephrology
- 5.4.7 Other Applications
-
5.5 By End Users
- 5.5.1 Diagnostic Laboratories
- 5.5.2 Hospitals and Clinics
- 5.5.3 Other End Users
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 BioMerieux
- 6.1.2 Danaher Corporation
- 6.1.3 F. Hoffmann-La Roche AG
- 6.1.4 Becton, Dickinson and Company
- 6.1.5 Bio-Rad Laboratories Inc.
- 6.1.6 Abbott
- 6.1.7 Sysmex Corporation
- 6.1.8 Siemens Healthineers AG
- 6.1.9 Thermo Fischer Scientific Inc.
- 6.1.10 Seegene Inc.
- 6.1.11 Ortho Clinical Diagnostics
- 6.1.12 Co-Diagnostics Inc.
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityMexico In-Vitro Diagnostics Industry Segmentation
As per the scope of this report, in vitro diagnostics involves medical devices and consumables that are utilized to perform in vitro tests on various biological samples. They are used for the diagnosis of various medical conditions, such as chronic diseases.
The Mexican in vitro diagnostics market is segmented by technique, product, usability, application, and end users. By technique, the market is segmented into clinical chemistry, molecular diagnostics, immunodiagnostics, hematology, and other techniques. By product, the market is segmented into instruments, reagents, and other products. By usability, the market is segmented into disposable IVD devices and reusable IVD devices. By application, the market is segmented into infectious disease, cancer/oncology, cardiology, autoimmune disease, diabetes, nephrology, and other applications. By end users, the market is segmented into diagnostic laboratories, hospitals and clinics, and other end users. The report offers the value (in USD) for the above segments.
| By Technique | Clinical Chemistry |
| Molecular Diagnostics | |
| Immuno Diagnostics | |
| Hematology | |
| Other Techniques | |
| By Product | Instrument |
| Reagent | |
| Other Products | |
| By Usability | Disposable IVD Devices |
| Reusable IVD Devices | |
| By Application | Infectious Disease |
| Cancer/Oncology | |
| Cardiology | |
| Autoimmune Disease | |
| Diabetes | |
| Nephrology | |
| Other Applications | |
| By End Users | Diagnostic Laboratories |
| Hospitals and Clinics | |
| Other End Users |
Mexico In-Vitro Diagnostics Market Research Faqs
How big is the Mexico In-Vitro Diagnostics Market?
The Mexico In-Vitro Diagnostics Market size is expected to reach USD 2.07 billion in 2024 and grow at a CAGR of 7.18% to reach USD 2.93 billion by 2029.
What is the current Mexico In-Vitro Diagnostics Market size?
In 2024, the Mexico In-Vitro Diagnostics Market size is expected to reach USD 2.07 billion.
Who are the key players in Mexico In-Vitro Diagnostics Market?
BioMérieux, Bio-Rad Laboratories, Inc., Sysmex Corporation, Thermo Fisher Scientific Inc. and Abbott are the major companies operating in the Mexico In-Vitro Diagnostics Market.
Which is the fastest growing region in Mexico In-Vitro Diagnostics Market?
Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Mexico In-Vitro Diagnostics Market?
In 2024, the North America accounts for the largest market share in Mexico In-Vitro Diagnostics Market.
What years does this Mexico In-Vitro Diagnostics Market cover, and what was the market size in 2023?
In 2023, the Mexico In-Vitro Diagnostics Market size was estimated at USD 1.92 billion. The report covers the Mexico In-Vitro Diagnostics Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Mexico In-Vitro Diagnostics Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Mexico In-Vitro Diagnostics Industry Report
Statistics for the 2024 Mexico In-Vitro Diagnostics market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Mexico In-Vitro Diagnostics analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
